Dnmt3A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| DNA Methyltransferase 3 Alpha | |
|---|---|
| Gene Symbol | DNMT3A |
| Full Name | DNA Methyltransferase 3 Alpha |
| Chromosome | 2p23 |
| NCBI Gene ID | 1785 |
| OMIM | 602950 |
| Ensembl ID | ENSG00000119772 |
| UniProt ID | Q9Y6K4 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, ALS, Tauopathy |
DNMT3A (DNA Methyltransferase 3A) is a de novo DNA methyltransferase that establishes new DNA methylation patterns during development and in adult tissues[^1]. It is crucial for genomic imprinting, X-chromosome inactivation, and silencing of repetitive elements.
In the brain, DNMT3A plays important roles in neuronal differentiation, synaptic plasticity, and learning and memory[^2]. Its dysfunction is implicated in neurodevelopmental disorders and neurodegenerative diseases.
DNMT3A encodes DNA methyltransferase 3 alpha, a de novo DNA methyltransferase that establishes new DNA methylation patterns during development and in adult tissues. DNMT3A is crucial for epigenetic regulation of gene expression in neurons and is involved in synaptic plasticity, memory formation, and genomic imprinting.
High expression in brain, particularly in hippocampus, cortex, and cerebellum. Expressed in neurons during development and in adulthood.
| Disease | Mechanism | References |
|---|---|---|
| Alzheimer's Disease | DNMT3A deficiency leads to memory impairment | [1] |
| Parkinson's Disease | Altered DNA methylation in PD brains | [2] |
| ALS | DNMT3A mutations cause early-onset ALS | [3] |
| Tauopathy | DNMT3A regulates tau pathology | [4] |
DNMT3A modulators are being explored for:
The study of Dnmt3A Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Feng, J., et al. (2010). Dnmt3a in the brain. Nature Neuroscience, 13(4), 423-430.
[2] Liu, L., et al. (2021). DNA methylation in Parkinson's disease. npj Parkinson's Disease, 7(1), 58.
[3] Takase, K., et al. (2020). DNMT3A mutations in ALS. Neurology, 95(15), e2078-e2089.
[4] Lu, Z., et al. (2013). DNA methylation and tau pathology. Journal of Alzheimer's Disease, 37(3), 457-464.
DNMT3A (DNA Methyltransferase 3A) is a de novo DNA methyltransferase that establishes DNA methylation patterns during development and cellular differentiation. Unlike DNMT1 (maintenance methyltransferase), DNMT3A establishes new methylation marks on unmethylated DNA.
DNMT3A functions in the brain to regulate gene expression during neurodevelopment, neural stem cell differentiation, and neuronal plasticity. It works with DNMT3B and DNMT3L to establish tissue-specific methylation patterns.
Alzheimer's Disease: DNMT3A expression and activity are altered in AD brains. DNA methylation changes are observed in AD-related genes, including those involved in amyloid processing, tau phosphorylation, and synaptic function. These changes may contribute to disease progression.
Parkinson's Disease: DNMT3A regulates genes involved in dopaminergic neuron survival and function. Methylation changes are observed in PD brains.
Huntington's Disease: DNMT3A contributes to transcriptional dysregulation in HD. The mutant huntingtin protein interacts with DNMT3A, altering its function.
Rett Syndrome: DNMT3A mutations cause a Rett-like syndrome, highlighting its critical role in neurodevelopment.
DNMT inhibitors (e.g., 5-azacytidine, decitabine) are being explored for neurodegenerative diseases. These compounds can reverse aberrant DNA methylation patterns and restore gene expression.
Understanding the specific gene targets of DNMT3A in different neurodegenerative contexts is a priority. Developing brain-penetrant DNMT inhibitors with improved specificity is ongoing.
The field of epigenetics has emerged as a key area in understanding neurodegenerative diseases. DNA methylation patterns are dynamically regulated in the brain, and alterations in these patterns are increasingly recognized as contributors to disease pathogenesis.
Transgenic mouse models lacking DNMT3A in neural progenitor cells show altered brain development and behavior. These models are used to study the role of DNA methylation in neurodegeneration.
DNA methylation marks in peripheral tissues (blood, CSF) are being investigated as potential biomarkers for neurodegenerative disease diagnosis and progression.
Several clinical trials are exploring epigenetic therapies, including HDAC inhibitors and DNMT inhibitors, for neurodegenerative diseases. Early-phase trials have shown some promise.